Steroid dexamethasone approved for use in COVID-19 treatment in U.K.

According to scientists, the drug has been proven to reduce the risk of death significantly in COVID-19 patients on ventilation by as much as 35% and patients on oxygen by 20%.

Updated - June 18, 2020 03:08 pm IST - London

A close-up of a box of Dexamethasone tablets in a pharmacy on June 16, 2020 in Cardiff, United Kingdom.

A close-up of a box of Dexamethasone tablets in a pharmacy on June 16, 2020 in Cardiff, United Kingdom.

The U.K. government on Wednesday authorised the State-funded National Health Service (NHS) to use steroid , the world’s first coronavirus treatment proven to reduce the risk of death among severely ill patients.

 

The Department of Health said the cheap and widely available anti-inflammatory steroid has been immediately approved to treat all hospitalised COVID-19 patients requiring oxygen, including those on ventilators, after an Oxford University trial confirmed positive results on Tuesday .

U.K. Prime Minister Boris Johnson hailed the government-funded trial as the biggest breakthrough, which has greatly reduced patients’ chances of dying from COVID-19.

“I am proud of these British scientists, backed by UK government funding, who have led the first, robust clinical trial anywhere in the world to find a coronavirus treatment proven to reduce the risk of death,” he said.

Also read: Indian doctors express cautious endorsement for dexamethasone for COVID-19

According to scientists, the drug has been proven to reduce the risk of death significantly in COVID-19 patients on ventilation by as much as 35% and patients on oxygen by 20%.

“The standard treatment for COVID-19 will include dexamethasone, helping save thousands of lives while we deal with this terrible virus,” said UK Health Secretary Matt Hancock.

This astounding breakthrough is testament to the incredible work being done by our scientists behind the scenes, he said.

The drug has also been added to the U.K. government’s parallel export list, which bans companies from buying medicines meant for U.K. patients and selling them on for a higher price in another country.

This will protect supply for U.K. patients by enforcing regulatory action on those who flout the restrictions, the Department of Health said.

The trial formed part of the 2.1-million pounds Randomised Evaluation of COVid-19 thERapY (RECOVERY) trial, backed by the U.K. government to explore innovative medicines in the fight against the novel coronavirus.

With over 177,000 patients enrolled, it is described as the largest randomised clinical trial anywhere in the world and will continue to trial other medicines, such as azithromycin and lopinavir-ritonavir.

“The RECOVERY trial is an outstanding example of the UK leading the world with an impressive study capable of delivering robust answers to critical questions. Although these data have not yet been peer-reviewed,” said UK Deputy Chief Medical Officer Professor Jonathan Van-Tam.

The positive findings on dexamethasone follow the disappointing findings on hydroxychloroquine. Together these two results illustrate the power of properly conducted clinical trials and the inherent danger of assuming things work without robust data, he said.

The medical expert said the dexamethasone findings are very encouraging because the signal on reduced mortality applies to many of the patients admitted to hospitals and the drug is comparatively low priced and available worldwide.

The UK government believes the trial will impact the global response to the coronavirus pandemic.

The vital information collected by UK researchers will also be used by other countries to reduce mortality rates worldwide, the Department of Health said.

The RECOVERY trial reported the findings of 2,104 patients randomised to dexamethasone in comparison with 4,321 patients randomised allocated to usual standard of care alone.

The trial has reported at a dose of 6mg dexamethasone once a day for up to 10 days or discharge if sooner. No benefit is seen for patients hospitalised and not on oxygen.

The drug, according to the scientists, is inexpensive, on the shelf, and can be used immediately to save lives worldwide.

WADA

However, the drug is banned in-competition by the World Anti-Doping Agency (WADA) but its usage is allowed out-of-competition if athletes have the requisite Therapeutic Usage Exemption (TUE).

Asian bronze-winning Indian javelin thrower Davinder Singh Kang is currently under provisional suspension after returning positive for the substance in an in-competition test conducted last year.

In 2017, Real Madrid star Sergio Ramos had tested positive for the drug during the Champions League but was let off after offering an apology for the team doctor’s failure to disclose the medication he had taken.

0 / 0
Sign in to unlock member-only benefits!
  • Access 10 free stories every month
  • Save stories to read later
  • Access to comment on every story
  • Sign-up/manage your newsletter subscriptions with a single click
  • Get notified by email for early access to discounts & offers on our products
Sign in

Comments

Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.

We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.